ANEB
Anebulo Pharmaceuticals, Inc.Company Information
- Company Name
- Anebulo Pharmaceuticals, Inc.
- CIK
- CIK0001815974
- Category
- Non-accelerated filer<br>Smaller reporting company<br>Emerging growth company
- Ticker: Exchange
- ANEB: Nasdaq
- Fiscal Year End
- June 30
- Owner Organization
- 03 Life Sciences
- SIC
- 2834
- SIC Description
- Pharmaceutical Preparations
- Ticker
- ANEB
SEC filing data through
Insider Sentiment
- Last purchase
- 2024-12-23
- Last sale
- —
- Shares purchased (TTM)
- 10,101,010
- Shares sold (TTM)
- 0
Institutional Sentiment
- As of
- 2025-12-31
- Institutional shares owned
- 22,208,686
- Shares outstanding
- 41,084,731
- Ownership
- 54.06%
Earnings Market Reaction
- Filing date
- 2026-02-12
- Price on filing date
- —
- 1-month reaction
- -4.21%
- 3-month reaction
- -3.16%
Balance Sheet
Values in millions ($)| Line item | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 | 2023-09-30 | 2023-06-30 | 2023-03-31 | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Trend |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Assets | ||||||||||||||||||
| Cash And Cash Equivalents At Carrying Value | 9 | 10 | 12 | 13 | 15 | 1 | 3 | 5 | 7 | 9 | 11 | - | ||||||
| Cash | - | - | - | - | - | - | - | - | - | - | 11 | 14 | ||||||
Assets Current | ||||||||||||||||||
| Assets Current | 9 | 11 | 12 | 14 | 15 | 2 | 4 | 5 | 7 | - | 12 | - | ||||||
| Grants Receivable | - | - | - | - | 0 | 0 | - | - | - | - | - | - | ||||||
| Prepaid Expense Current | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | ||||||
Assets Noncurrent | ||||||||||||||||||
| Other Assets Noncurrent | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 1 | - | - | - | ||||||
| Assets | 9 | 11 | 12 | 14 | 16 | 2 | 4 | 6 | 8 | 9 | 12 | 14 | ||||||
Liabilities And Stockholders Equity | ||||||||||||||||||
| Accounts Payable Current | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 1 | ||||||
Liabilities Current | ||||||||||||||||||
| Accrued Liabilities Current | 1 | 0 | 0 | 0 | 1 | 0 | 0 | 1 | 1 | 0 | 1 | 1 | ||||||
| Liabilities | 1 | 1 | 0 | 1 | 1 | 1 | 0 | 1 | 1 | 1 | 1 | 1 | ||||||
| Common Stock Value | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
Stockholders Equity | ||||||||||||||||||
| Additional Paid In Capital | 86 | 86 | 86 | 85 | 85 | 69 | 69 | 69 | 69 | 68 | 68 | 68 | ||||||
| Stockholders Equity | 8 | 10 | 12 | 13 | 15 | 2 | 4 | 5 | 6 | 8 | 11 | 13 | ||||||
| Retained Earnings Accumulated Deficit | -78 | -76 | -74 | -72 | -70 | -68 | -65 | -64 | -62 | -60 | -57 | -55 | ||||||
| Liabilities And Stockholders Equity | 9 | 11 | 12 | 14 | 16 | 2 | 4 | 6 | 8 | 9 | 12 | 14 | ||||||
| Preferred Stock Par Or Stated Value Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||||
| Preferred Stock Shares Authorized | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 0 | 2 | ||||||
| Preferred Stock Shares Issued | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Preferred Stock Shares Outstanding | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Common Stock Par Or Stated Value Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||||
| Common Stock Shares Authorized | 75 | 75 | 75 | 50 | 50 | 50 | 50 | 50 | 40 | 40 | 40 | 40 | ||||||
| Common Stock Shares Issued | 41 | 41 | 41 | 41 | 41 | 26 | 26 | 26 | 26 | 26 | 26 | 26 | ||||||
| Shares Outstanding | 41 | 41 | 41 | 41 | 41 | 26 | 26 | 26 | 26 | 26 | 26 | 26 | ||||||
Select a line item above to chart it.
Recent filings
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
Financial statements beyond 3 years are for subscribers only.
Unlock 17+ years of income statements, balance sheets, and cash flow statements
Start 7-day free trialAnebulo Pharmaceuticals, Inc. (ANEB) — SEC Financial Statements & Analysis
Anebulo Pharmaceuticals, Inc. (ANEB) is a pharmaceutical preparations company, incorporated in DE. Anebulo Pharmaceuticals, Inc. trades on Nasdaq as: ANEB. Anebulo Pharmaceuticals, Inc. (ANEB)'s most recent SEC filing is a Form 10-Q for the period ended 2025-12-31, filed with the SEC on 2026-02-12. Based on that filing, Anebulo Pharmaceuticals, Inc. carries a market cap of $41.50M, a P/E ratio of -5.20x, a P/B ratio of 5.23x, an enterprise value of $32.45M, and an EV/EBITDA multiple of -3.57x. On profitability, it posts a Return on Equity (ROE) of -69.69%, a Return on Assets (ROA) of -63.16%, and a Return on Invested Capital (ROIC) of -2464.82%. Per share, it reports EPS of $-0.19, diluted EPS of $-0.19, free cash flow per share of $-0.14, and a dividend per share of $0.00. Over the trailing year, it posted net income growth of 4.06% year-over-year and EPS growth of -30.56% year-over-year. On the balance sheet, it maintains an interest coverage ratio of -30.60x, free cash flow of $-5.84M (TTM), and net debt of $-9.04M. Figures sourced from SEC EDGAR.
- Market Cap
- $41.50M
- P/E TTM
- -5.20x
- EPS TTM
- $-0.19
- P/B TTM
- 5.23x
- ROE TTM
- -69.69%
- ROA TTM
- -63.16%
- Free Cash Flow TTM
- $-5.84M
Data as of 2025-12-31 · Source: SEC EDGAR
Frequently Asked Questions
What industry is Anebulo Pharmaceuticals, Inc. in?
Anebulo Pharmaceuticals, Inc. (ANEB) operates in the Pharmaceutical Preparations industry.
What exchange does ANEB trade on?
Anebulo Pharmaceuticals, Inc. (ANEB) trades on the Nasdaq.
Where is Anebulo Pharmaceuticals, Inc. incorporated?
Anebulo Pharmaceuticals, Inc. is incorporated in DE.
When was Anebulo Pharmaceuticals, Inc. (ANEB)'s most recent SEC filing?
Anebulo Pharmaceuticals, Inc. (ANEB)'s most recent SEC filing is a Form 10-Q for the period ended 2025-12-31, filed with the SEC on 2026-02-12.
What is ANEB's market cap?
Anebulo Pharmaceuticals, Inc. (ANEB) has a market capitalization of $41.50M as of 2025-12-31.
What is ANEB's EPS (earnings per share)?
Anebulo Pharmaceuticals, Inc. (ANEB)'s trailing twelve month EPS is $-0.19 as of 2025-12-31.
What is ANEB's ROE (return on equity)?
Anebulo Pharmaceuticals, Inc. (ANEB)'s trailing twelve month Return on Equity (ROE) is -69.69% as of 2025-12-31.
What is ANEB's ROA (return on assets)?
Anebulo Pharmaceuticals, Inc. (ANEB)'s trailing twelve month Return on Assets (ROA) is -63.16% as of 2025-12-31.
What is ANEB's ROIC (return on invested capital)?
Anebulo Pharmaceuticals, Inc. (ANEB)'s trailing twelve month Return on Invested Capital (ROIC) is -2464.82% as of 2025-06-30.
What is ANEB's EV/EBITDA?
Anebulo Pharmaceuticals, Inc. (ANEB)'s trailing twelve month EV/EBITDA is -3.57x as of 2025-12-31.